Program
adagrasib
Also written as “Adagrasib”, “MRTX849” and “Eltrombopag + adagrasib”.
Its studies are mostly in Neoplasm Metastasis · Carcinoma, Non-Small-Cell Lung · Colorectal Neoplasms · Biliary Tract Neoplasms, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Bristol-Myers Squibb | 157 open or running | phase 3since Oct 28, 2020 | Dec 18, 2018 | Feb 16, 2028phase 2 · NCT07415031 |
| Zai Lab | 10 open or running | phase 1since Jan 13, 2022 | Jan 13, 2022 | none ahead |
Also a collaborator on its studies: aadi-bioscience-inc, Novartis and Boehringer Ingelheim.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 2 studies since Dec 18, 2018.
- Oct 28, 2020Phase 3 study in Carcinoma, Non-Small-Cell LungBristol-Myers Squibb · NCT04613596 · 626 planned · United States, Argentina, Australia and more
- Dec 21, 2020Phase 3 study in Carcinoma, Non-Small-Cell LungBristol-Myers Squibb · NCT04685135 · 453 enrolled · United States, Australia, Austria and more
- Mar 2, 2021Phase 3 study in Colorectal NeoplasmsBristol-Myers Squibb · NCT04793958 · 461 enrolled · United States, Argentina, Australia and more
- Jul 6, 2021Phase 1 study in Neoplasm MetastasisBristol-Myers Squibb · NCT04975256 · 7 enrolled · United States
- Dec 1, 2021Phase 1 study in Advanced Solid TumorBristol-Myers Squibb · NCT05178888 · 11 enrolled · United States
- Jan 13, 2022Zai Lab's first study: phase 1 study in Neoplasm MetastasisNew to Zai LabZai Lab · NCT05263986 · 22 enrolled · China
- Apr 12, 2023Phase 2 study in Neoplasm MetastasisBristol-Myers Squibb · NCT05853575 · 200 enrolled · United States, Brazil, Croatia and more
- Apr 12, 2023Phase 1 study in Neoplasm MetastasisBristol-Myers Squibb · NCT05840510 · 6 enrolled · United States
- Jun 20, 2023Phase 1 study in Healthy AdultsBristol-Myers Squibb · NCT05924152 · 16 enrolled · United States
- Aug 29, 2023Phase 2 study in Biliary Tract NeoplasmsBristol-Myers Squibb · NCT06024174 · 5 enrolled · United States, Australia, Finland and more
- Jan 24, 2025Phase 1 study in Healthy VolunteersBristol-Myers Squibb · NCT06801418 · 160 enrolled · United States
- Mar 7, 2025Phase 3 study in Carcinoma, Non-Small-Cell LungBristol-Myers Squibb · NCT06875310 · 630 planned · United States, Argentina, Australia and more
- Feb 11, 2026Phase 2 study in Solid TumorsBristol-Myers Squibb · NCT07415031 · 170 planned · United States, Australia, Belgium and more
- Jul 20, 2026Phase 1 study in Healthy ParticipantsBristol-Myers Squibb · NCT07723118 · 10 enrolled · United States
Ahead
- Feb 16, 2028Primary completion: phase 2 study in Solid TumorsBristol-Myers Squibb · NCT07415031
- Oct 31, 2028Primary completion: phase 3 study in Carcinoma, Non-Small-Cell LungBristol-Myers Squibb · NCT04613596
- Sep 7, 2029Primary completion: phase 3 study in Carcinoma, Non-Small-Cell LungBristol-Myers Squibb · NCT06875310
TargetBeta
“An orally available, small molecule inhibitor that targets the oncogenic KRAS substitution mutation, G12C, ”NCIt, by rule
“GTPase KRas inhibitor”ChEMBL 37, by rule
Other programs on KRAS
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| sotorasibrule | Amgen | phase 3 | 28 |
| olomorasib | Eli Lilly | phase 3 | 16 |
| divarasib | Hoffmann-La Roche | phase 3 | 13 |
| KRAS G12D Inhibitor VS-7375rule | Genfleet Therapeutics (Shanghai) | phase 3 | 12 |
| glecirasibrule | Allist Pharmaceuticals | phase 3 | 12 |
| calderasib | Merck | phase 3 | 12 |
| daraxonrasibrule | Revolution Medicines | phase 3 | 10 |
| garsorasibrule | InventisBio | phase 3 | 8 |
| KRAS G12D Inhibitor HRS-4642 | Jiangsu HengRui Medicine | phase 3 | 7 |
| zoldonrasibrule | Revolution Medicines | phase 3 | 6 |
| HRS-7058 | Jiangsu HengRui Medicine | phase 3 | 6 |
| opnurasibrule | Novartis | phase 3 | 5 |
Studies
All 16 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07723118Healthy Participants · United States | 1 | Completed | Bristol-Myers Squibb | Sep 8, 2026 | 10 |
| NCT07415031Solid Tumors · United States, Australia, Belgium and more | 2 | Recruiting | Bristol-Myers Squibb | Feb 16, 2028 | 170 |
| NCT06875310Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more | 3 | Recruiting | Bristol-Myers Squibb | Sep 7, 2029 | 630 |
| NCT06801418Healthy Volunteers · United States | 1 | Completed | Bristol-Myers Squibb | Jun 19, 2025 | 160 |
| NCT06024174Biliary Tract Neoplasms · United States, Australia, Finland and more | 2 | Terminated | Bristol-Myers Squibb | May 13, 2024 | 5 |
| NCT05924152Healthy Adults · United States | 1 | Completed | Bristol-Myers Squibb | Aug 9, 2023 | 16 |
| NCT05853575Neoplasm Metastasis · United States, Brazil, Croatia and more | 2 | Active, not recruiting | Bristol-Myers Squibb | Oct 30, 2026 | 200 |
| NCT05840510Neoplasm Metastasis · United States | 1 | Terminated | Bristol-Myers Squibb | Dec 27, 2024 | 6 |
| NCT05263986Neoplasm Metastasis · China | 1 | UNKNOWN | Zai Lab | Oct 31, 2023 | 22 |
| NCT05178888Advanced Solid Tumor · United States | 1 | Completed | Bristol-Myers Squibb | Jun 15, 2023 | 11 |
| NCT04975256Neoplasm Metastasis · United States | 1 | Terminated | Bristol-Myers Squibb | Nov 2, 2022 | 7 |
| NCT04793958Colorectal Neoplasms · United States, Argentina, Australia and more | 3 | Active, not recruiting | Bristol-Myers Squibb | Jan 16, 2026 | 461 |
| NCT04685135Carcinoma, Non-Small-Cell Lung · United States, Australia, Austria and more | 3 | Active, not recruiting | Bristol-Myers Squibb | Dec 30, 2023 | 453 |
| NCT04613596Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more | 3 | Recruiting | Bristol-Myers Squibb | Oct 31, 2028 | 626 |
| NCT04330664Neoplasm Metastasis · United States | 1 | Completed | Bristol-Myers Squibb | Jul 29, 2022 | 86 |
| NCT03785249Neoplasm Metastasis · United States, Puerto Rico | 2 | Active, not recruiting | Bristol-Myers Squibb | Jun 23, 2026 | 731 |
How it is read
Names in the registry
- “Adagrasib”, 12 entries
- “MRTX849”, 7 entries
- “Eltrombopag + adagrasib”, 1 entry
Conditions, from the studies’ own filings
- Neoplasm Metastasis, 6 studies
- Carcinoma, Non-Small-Cell Lung, 3 studies
- Colorectal Neoplasms, 1 study
- Biliary Tract Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.